Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (5 mcg/Day) Over 48 Weeks as add-on Controller Therapy on Top of Usual Care in Patients With Severe Persistent Asthma

NCT00776984 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT00776984
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00776984 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (5 mcg/Day) Over 48 Weeks as add-on Controller Therapy on Top of Usual Care in Patients With Severe Persistent Asthma
Lead sponsor
Boehringer Ingelheim
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2008
Completion date
Not reported
Enrollment
453 (actual)
Sites
75

Conditions

As the registry lists them; a condition with its own page is linked.

asthma